Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis.
about
Orthopedic gene therapy in 2008.Local effect of IL-4 delivery on polyethylene particle induced osteolysis in the murine calvarium.Clinical potential and challenges of using genetically modified cells for articular cartilage repair.Aseptic loosening.Stem cells as vehicles for orthopedic gene therapy.Gene therapy in orthopaedic surgery: the current status.Role of polyethylene particles in peri-prosthetic osteolysis: A review.Comparison of the roles of IL-1, IL-6, and TNFalpha in cell culture and murine models of aseptic loosening.Blockade of JNK and NFAT pathways attenuates orthopedic particle-stimulated osteoclastogenesis of human osteoclast precursors and murine calvarial osteolysis.Novel host response therapeutic approaches to treat periodontal diseases.Anti-oxidation treatment of ultra high molecular weight polyethylene components to decrease periprosthetic osteolysis: evaluation of osteolytic and osteogenic properties of wear debris particles in a murine calvaria model.The central role of wear debris in periprosthetic osteolysis.Androgen receptor is a tumor suppressor and proliferator in prostate cancer.Alternative macrophage activation in periprosthetic osteolysis.Current state and future of joint replacements in the hip and knee.Periprosthetic osteolysis: genetics, mechanisms and potential therapeutic interventions.Periprosthetic osteolysis after total hip replacement: molecular pathology and clinical management.Pharmacologic augmentation of implant fixation in osteopenic bone.NF-κB decoy oligodeoxynucleotide inhibits wear particle-induced inflammation in a murine calvarial model.Gene Therapy for Cartilage Repair.In vivo osteoprotegerin gene therapy preventing bone loss induced by periodontitis.Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA.Cell-based osteoprotegerin therapy for debris-induced aseptic prosthetic loosening on a murine model.Extracellular matrix degradation and tissue remodeling in periprosthetic loosening and osteolysis: focus on matrix metalloproteinases, their endogenous tissue inhibitors, and the proteasome.Surface grafting of artificial joints with a biocompatible polymer for preventing periprosthetic osteolysis.Local RANKL gene transfer to the periodontal tissue accelerates orthodontic tooth movement.Protective effects of IL-1Ra or vIL-10 gene transfer on a murine model of wear debris-induced osteolysis.RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro.Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening.
P2860
Q33713231-AC46F9ED-BABE-4AD9-95E6-A065C4FB79B2Q33816055-E527B4BE-45BE-4004-80D3-CFE71B4FCDBDQ35090336-59196D0B-E435-4AAD-9A3C-93CA29E89DF4Q35629551-5A811BBD-598F-4F09-BB80-3086D6D940ACQ35629581-AC99F671-71DC-4DDE-B0DF-31E8B3D09004Q35630146-99DCD5E8-671B-4783-AFE9-4785D0490211Q35825373-EAAFD1B3-C889-4B90-BBDE-8B32027CE088Q35908576-02840561-8EB9-4DBA-9EC4-EFCF7D9DD99DQ36385024-557BEB46-D3E7-4C46-95F8-76C2B0DF12CBQ36703987-FE226041-15E5-4846-9E9A-EDC0171347DDQ36795335-B685D451-9DD3-4810-86A0-A5F42562BC52Q36796472-EC610E64-C92E-471C-B799-FE566829008CQ36858442-F7C7B3A5-B01E-47B2-8036-7EA19B900B86Q37118773-752B5B88-1921-4A29-A73C-B892284AA579Q37152851-D4975464-C020-4F63-8A35-DC852CC19820Q38044786-A62DA05F-0360-4DAA-93C3-F7EFE86B8FCAQ38152730-5B19268B-542F-4E96-B179-918FBEE78FEEQ38167678-337BCE91-B562-47B3-A4E2-4DD5EC7D3226Q38297927-ECDE1B6A-9B24-4394-A03D-9A06414F8191Q38526206-8E057389-BEA4-4B8B-AE05-E8487BE04965Q38958157-49079692-A4F3-4E20-A7FB-0DE2F1744CC1Q40534131-4FCDB171-F3DB-4727-A61A-48317CF5C0B5Q41905947-F1D17167-8B74-45AB-97D6-601453FBFEB2Q42755979-8807F629-430B-4CCF-BA0F-08FA23B7FE8AQ45122625-B48D9623-5A09-4A67-A4FB-6D6FA626E911Q45854964-13ED7737-C6D8-4A6B-B80E-0E3A342EA0C9Q45871730-CA439613-D912-4D89-8637-1718D73D13C2Q51426261-4F5C609D-5724-47F1-A602-DE2132539EC3Q51728955-F3CD52B9-6CC2-420B-9ADD-5DB6BAD33E91
P2860
Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis.
@en
Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis.
@nl
type
label
Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis.
@en
Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis.
@nl
prefLabel
Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis.
@en
Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis.
@nl
P2093
P2860
P1476
Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis.
@en
P2093
Edward M Schwarz
J Edward Puzas
J Jeffrey Goater
Randy N Rosier
Regis J O'Keefe
P2860
P304
P356
10.1016/S0736-0266(01)00083-3
P577
2002-03-01T00:00:00Z